Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma

LEP is a promising alternative as a non-first-line therapeutic regimen for patients with refractory BTC. Furthermore, well-designed prospective clinical trials with a control arm are still needed to obtain more evidences to confirm the efficacy and safety of this particular regimen as well as the role of PDL1 expression.